Abstract 1580P
Background
There is concern that the incidence of oesophageal adenocarcinoma (OAC) in patients under 50, described as early onset (EO) OAC, may be rising steadily. Epidemiological studies suggest that EO-OAC patients present with higher-stage disease compared to late-onset patients, receive more aggressive treatment but may have poorer survival outcomes. We utilised Whole Genome Sequencing (WGS) and RNA-seq to investigate if EO-OAC represents a distinct biological entity compared to late-onset disease.
Methods
We obtained WGS and clinical data for stage and treatment matched OAC patients who received neoadjuvant chemotherapy prior to surgical resection (n=29 patients ≤50 years and n=144 patients ≥70 years) from the OCCAMS consortium. We performed statistical analysis between age groups using chi-squared testing with FDR correction for copy number aberrations (CNA), insertions and deletions (INDELS) and single nucleotide variants (SNV), assessing gene-level mutations and mutational burden considering coding genes only, prior to assessing 76 OAC driver genes as described by Frankell et al., 2019. Biological pathways between age groups were assessed for n=66 patients using available RNASeq data and Gene Set Enrichment Analysis (GSEA).
Results
Our results indicate that EO-OAC had a lower combined mutational burden (Wilcoxon p=0.0204) and lower indel counts (Wilcoxon p=0.0031) compared to late-onset patients. When considering gene-level mutations for SNV, CNA, INDELS and 76 OAC driver genes (Frankell et al., 2019), multiple analyses showed genes at a nominal p-value <0.05 between age groups yet none reached significance at FDR p-value <0.25. GSEA indicated 179 enriched pathways, several related to immune signalling for EO-OAC at nominal p-value <0.05 and a higher DNA Damage Immune Response (DDIR) assay score in EO-OAC (p=0.012).
Conclusions
Our comparison of early and late-onset OAC using WGS and RNA-seq data highlights the possibility of EO-OAC as a separate biological entity, with potentially enhanced immune signalling. Future work in larger sample cohorts and the investigation of clinically relevant gene and mutational signatures is required to further assess molecular differences between early and late onset OAC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1655P - Nampt inhibitors re-sensitize MAP17 expressing pancreas tumors
Presenter: Julia Martinez Perez
Session: Poster session 22
1656P - Targeting NPC1L1 rescues anti-tumor immunity and improves immunotherapeutic efficacy in pancreatic cancer
Presenter: Houjie Liang
Session: Poster session 22
1657P - Understanding the role of SAGA and mediator in the resistance to Pdk1 deletion in PDAC
Presenter: Katarina Ondrejkova
Session: Poster session 22
1658P - Molecular subtyping of familial pancreatic ductal adenocarcinoma identifies novel pathogenic germline variants
Presenter: Julie Earl
Session: Poster session 22
1659P - The use of liquid biopsy in patients with advanced pancreatic cancer (PDAC) to guide enrollment in phase I clinical trials
Presenter: Octave Letissier
Session: Poster session 22
1660P - Squalene epoxidase promotes pancreatic cancer growth by attenuating ER stress and activating lipid rafts-regulated Src/PI3K/Akt signalling pathway
Presenter: Ruiyuan Xu
Session: Poster session 22
1661P - Precision medicine for pancreatic cancer: A clinical study validating EUS biopsies
Presenter: Joanne Lundy
Session: Poster session 22
1662P - Targeting stress granule formation as a synthetic lethality strategy for kras-induced pancreatic cancer initiation
Presenter: Patricia Santofimia
Session: Poster session 22
1663P - Role of next-generation sequencing somatic assays in patients with advanced pancreatic cancer
Presenter: Rafaela Naves
Session: Poster session 22
1664P - Italian Association for Medical Oncology (AIOM) guideline application in real-world: Multi-institutional based survey of adjuvant and first-line pancreatic ductal adenocarcinoma treatment in Italy (GARIBALDI) - survival analyses in the metastatic cohort
Presenter: Michele Reni
Session: Poster session 22